Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

970
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

863
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
863
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

749
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
749
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

[Global warming : a cardiovascular risk factor in it's own right].

Revue medicale de Liege·2026
Same author

Evaluating the feasibility of a novel multidisciplinary residential rehabilitation program for managing fatigue in patients with spontaneous coronary artery dissection.

European journal of cardiovascular nursing·2026
Same author

Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population.

European heart journal·2026
Same author

Exploring Sex-Specific High-Sensitivity Cardiac Troponin Thresholds for Rule-Out of Non-ST-Elevation Myocardial Infarction.

Clinical chemistry·2026
Same author

Vessel-Specific Differences in Fractional Flow Reserve Among Intermediate Coronary Lesions.

Journal of clinical medicine·2026
Same journal

Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.

The New England journal of medicine·2026
Same journal

Opportunities to Combat the Chronic Pain-Opioid Use Disorder Syndemic.

The New England journal of medicine·2026
Same journal

The Invisible Load of Cognitive Symptoms.

The New England journal of medicine·2026
Same journal

Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.

The New England journal of medicine·2026
Same journal

Cat Scratch Disease.

The New England journal of medicine·2026
Same journal

Declarations of Independence - Physicians and the U.S. Body Politic, 1776-2026.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Sep 9, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.

John Munkhaugen1,2, Anna Meta D Kristensen3, Sigrun Halvorsen4,5

  • 1Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.

The New England Journal of Medicine
|September 1, 2025
PubMed
Summary
This summary is machine-generated.

Beta-blocker therapy after myocardial infarction significantly reduced the risk of death or major adverse cardiovascular events in patients with preserved ejection fraction. This finding supports beta-blocker use in post-myocardial infarction care.

More Related Videos

A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

3.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.1K

Related Experiment Videos

Last Updated: Sep 9, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K
A Modified Simple Method for Induction of Myocardial Infarction in Mice
04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

3.8K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.1K

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Established beta-blocker evidence predates modern reperfusion and secondary prevention strategies.
  • Current guidelines require updated evidence for post-myocardial infarction (MI) management.

Purpose of the Study:

  • To evaluate the long-term efficacy of beta-blocker therapy after MI.
  • To assess the impact of beta-blockers on mortality and major adverse cardiovascular events (MACE) in patients with left ventricular ejection fraction (LVEF) ≥40%.

Main Methods:

  • Open-label, randomized trial with blinded endpoint evaluation in Denmark and Norway.
  • 5574 patients with MI and LVEF ≥40% randomized 1:1 to beta-blockers or no beta-blockers within 14 days.
  • Primary endpoint: composite of all-cause death or MACE (MI, revascularization, stroke, heart failure, ventricular arrhythmias).

Main Results:

  • Median follow-up of 3.5 years.
  • Beta-blocker group (n=2783) had 14.2% primary endpoint events vs. 16.3% in no-beta-blocker group (n=2791) (HR 0.85; P=0.03).
  • Reduced risk of MI (HR 0.73) observed with beta-blockers; no significant differences in all-cause death or other MACE components. Safety outcomes were similar.

Conclusions:

  • Beta-blocker therapy significantly lowers the risk of death or MACE in MI patients with LVEF ≥40%.
  • Results support continued use of beta-blockers as a cornerstone of post-MI secondary prevention.